Utilization of Food-Derived β-Glucans to Prevent and Treat Non-Alcoholic Fatty Liver Disease (NAFLD)

Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease nowadays. Currently, there is no officially approved drug to treat NAFLD. In view of the increasing global prevalence of NAFLD and an absence of treatments, the development of effective treatments is of utmost importance. beta-glucan, a natural bioactive polysaccharide, has demonstrated hepatoprotective effects in NAFLD prevention and treatment. This review solely focuses on gathering the published preclinical animal studies that demonstrated the anti-liver injury, anti-steatotic, antiinflammatory, anti-fibrotic, and antioxidant activities of fi-glucan. The impact of beta-glucan on gut microbiota and its metabolites including short-chain fatty acids and bile acids as the underlying mechanism for its bioactive beneficial effect on NAFLD is also explored. Given the limited knowledge of beta-glucan on anti-fibrotic activity, bile acid metabolism, and gut microbiota function, additional relevant research is highly encouraged to lay a solid foundation for the use of food-derived beta-glucan as a functional food for NAFLD. It is envisaged that further investigation of food-derived beta-glucan in human clinical studies should be carried out for its wider utilization.

Automated summary

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease with no approved drug treatment. This review focuses on preclinical animal studies that demonstrate the beneficial effects of food-derived beta-glucan in preventing and treating NAFLD. Beta-glucan shows hepatoprotective, anti-steatotic, anti-inflammatory, anti-fibrotic, and antioxidant activities, and may function through its impact on gut microbiota and metabolites.